EIDOS THERAPEUTICS

Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the growing unmet need in diseases caused by transthyretin amyloidosis, or ATTR. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into 3 distinct categories: wild-type ATTR cardiomyopathy (wtATTR-CM), variant ATTR cardiomyopathy (vATTR-CM), and ATTR polyneuropathy (ATTR-PN). The estimated worldwide prevalence of each condition is 400,000 patients, 40,000 patients, and 10,000 patients, respectively. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care. We seek to treat this well-defined family of diseases at their collective source by stabilizing transthyretin... Eidos Therapeutics is developing a small molecule named acoramidis (AG10), which was designed by..

Primary location: San Francisco United States